Filtering

Page: () 1 ... 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 ... 43 ()
ECCO'17 BarcelonaDOP020: Higher vedolizumab levels are associated with deep remission in patients with Crohn’s Disease and Ulcerative Colitis on maintenance therapy with vedolizumab
Year: 2017
Source: ECCO'17 Barcelona
Authors: Yarur A.
Patient reported outcomes, Therapeutic drug monotoring, Pharmacokinetics, Treat to tatrget, Vedolizumab
Files: 1
ECCO'16 DOPDOP020: Prediction of clinical and endoscopic remission after autologous stem cell transplantation in treatment refractory Crohn’s disease: pooled results from the ASTIC trial
Year: 2016
Source: ECCO'16 DOP
Authors: Lindsay J.
stem cell transplantation/therapy, clinical trials, Crohn's Disease
Files: 1
ECCO'16 DOPDOP021: Long term efficacy of autologous haematopoietic stem cells transplantation for refractory Crohn’s disease: ten years of Milan experience without CD34+ cell selection.
Year: 2016
Source: ECCO'16 DOP
Authors: Cassinotti A.
stem cell transplantation/therapy, clinical trials, Crohn's Disease
Files: 1
ECCO'16 DOPDOP022: Targeting Immune Cell Metabolism: LYC-30937, A Novel Therapeutic Approach for Inflammatory Bowel Disease
Year: 2016
Source: ECCO'16 DOP
Authors: Higgins P.
clinical trial
Files: 1
ECCO'17 BarcelonaDOP022: Vedolizumab (VDZ) and anti-α treatment effectiveness in patients with IBD treated in Germany: A retrospective chart review
Year: 2017
Source: ECCO'17 Barcelona
Authors: Ehehalt R.
Crohn's disease, Anti-TNF agents,Vedolizumab
Files: 1
ECCO'17 BarcelonaDOP023: Predictors of clinical and endoscopic response with vedolizumab for the treatment of moderately-severely active Ulcerative Colitis: Results from the US VICTORY consortium
Year: 2017
Source: ECCO'17 Barcelona
Authors: Dulai P.
Ulcerative colitis, Patient reported outcomes, Vedolizumab
Files: 1
ECCO'16 DOPDOP023: Safety and efficacy of a novel i.v. targeted pegylated liposomal prednisolone (Nanocort): results from a phase 2a study in patients with active ulcerative colitis
Year: 2016
Source: ECCO'16 DOP
Authors: Vermeire S.
Ulcerative Colitis, corticosteroids, clinical trial
Files: 1
ECCO'16 DOPDOP024: Electrical vagus nerve stimulation as an innovative treatment in inflammatory bowel diseases
Year: 2016
Source: ECCO'16 DOP
Authors: Bonaz B.
Crohn's Disease
Files: 1
ECCO'17 BarcelonaDOP024: Vedolizumab clinical and post-marketing safety experience of opportunistic infections
Year: 2017
Source: ECCO'17 Barcelona
Authors: Ng S.
Concomitant infections, Vedolizumab
Files: 1
ECCO'16 DOPDOP025: Clinical response to anti-MMP9 antibody (GS-5745) is accompanied by histologic improvement in ulcerative colitis
Year: 2016
Source: ECCO'16 DOP
Authors: Levesque B.
histological healing
Files: 1
ECCO'17 BarcelonaDOP025: Efficacy of vedolizumab on extraintestinal manifestation in patients with Inflammatory Bowel Disease: A post-hoc analysis of the OBSERV-IBD cohort from the GETAID
Year: 2017
Source: ECCO'17 Barcelona
Authors: Tadbiri S.
Vedolizumab, Arthralgia, Perianal disease, other extraintestinal manifestations
Files: 1
ECCO'17 BarcelonaDOP026: Sustained remission with vedolizumab in patients with Moderately to Severely active Ulcerative Colitis: A GEMINI 1 post hoc analysis of Week 14 remitters
Year: 2017
Source: ECCO'17 Barcelona
Authors: Stallmach A.
Ulcerative colitis, Vedolizumab
Files: 1
Page: () 1 ... 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 ... 43 ()